[go: up one dir, main page]

MX2009005414A - Formulaciones liquidas de anticuerpo antirrabico. - Google Patents

Formulaciones liquidas de anticuerpo antirrabico.

Info

Publication number
MX2009005414A
MX2009005414A MX2009005414A MX2009005414A MX2009005414A MX 2009005414 A MX2009005414 A MX 2009005414A MX 2009005414 A MX2009005414 A MX 2009005414A MX 2009005414 A MX2009005414 A MX 2009005414A MX 2009005414 A MX2009005414 A MX 2009005414A
Authority
MX
Mexico
Prior art keywords
antibody formulations
liquid anti
formulations
rabies antibody
rabies
Prior art date
Application number
MX2009005414A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Willem Egbert Marissen
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MX2009005414A publication Critical patent/MX2009005414A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a formulaciones farmacéuticas de anticuerpo, en particular formulaciones líquidas farmacéuticas que comprenden anticuerpos de virus de la rabia. Las formulaciones se pueden usar en la profilaxis post-exposición de la rabia.
MX2009005414A 2006-12-05 2007-12-04 Formulaciones liquidas de anticuerpo antirrabico. MX2009005414A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87289206P 2006-12-05 2006-12-05
EP06125400 2006-12-05
PCT/EP2007/063244 WO2008068246A1 (en) 2006-12-05 2007-12-04 Liquid anti-rabies antibody formulations

Publications (1)

Publication Number Publication Date
MX2009005414A true MX2009005414A (es) 2009-06-01

Family

ID=39092188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005414A MX2009005414A (es) 2006-12-05 2007-12-04 Formulaciones liquidas de anticuerpo antirrabico.

Country Status (13)

Country Link
US (1) US7959922B2 (es)
EP (1) EP2088997B1 (es)
JP (1) JP5410985B2 (es)
KR (1) KR101522036B1 (es)
CN (1) CN101557799B (es)
AU (1) AU2007328960B2 (es)
CA (1) CA2668947C (es)
CU (1) CU23795A3 (es)
EA (1) EA017549B1 (es)
IL (1) IL199004A (es)
MX (1) MX2009005414A (es)
WO (1) WO2008068246A1 (es)
ZA (1) ZA200902772B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636265A2 (en) 2003-06-25 2006-03-22 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
CN102139106B (zh) * 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
JP5574706B2 (ja) * 2006-06-06 2014-08-20 クルセル ホランド ベー ヴェー ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
US7959922B2 (en) 2006-12-05 2011-06-14 Crucell Holland B.V. Liquid anti-rabies antibody formulations
JP2010085126A (ja) * 2008-09-29 2010-04-15 Adtec Kk 狂犬病ウイルス中和抗体価判定具および狂犬病ウイルス中和抗体価の測定方法
WO2011028961A2 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
HK1198689A1 (en) 2011-10-25 2015-05-29 Prothena Biosciences Limited Antibody formulations and methods
MY167233A (en) * 2012-03-07 2018-08-14 Lilly Co Eli Il-17 antibody formulation
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JP7159642B2 (ja) * 2018-06-26 2022-10-25 東ソー株式会社 カラムの抗体に対する保持力の測定方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
EP4165082A4 (en) 2020-06-12 2024-07-10 Nanjing Leads Biolabs Co., Ltd. TNFR2-BINDING ANTIBODIES AND USES THEREOF
CN114748618B (zh) * 2022-04-02 2024-07-19 重庆智翔金泰生物制药股份有限公司 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402029B1 (en) 1989-06-08 1994-01-12 The Wistar Institute Monoclonal antibodies for post exposure treatment of rabies
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
ATE230850T1 (de) 1996-10-08 2003-01-15 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
AU2002332600B2 (en) 2001-08-21 2007-03-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
WO2005023849A2 (en) 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
JP4671864B2 (ja) * 2003-10-09 2011-04-20 中外製薬株式会社 タンパク質溶液の安定化方法
ATE518888T1 (de) * 2003-10-09 2011-08-15 Chugai Pharmaceutical Co Ltd Stabilisierte lösung mit hoher igm-konzentration
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
CN102139106B (zh) * 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
KR101280273B1 (ko) * 2005-04-18 2013-07-15 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정화된 항-ｂ형 간염 바이러스 (ｈｂｖ) 항체 제형
US7959922B2 (en) 2006-12-05 2011-06-14 Crucell Holland B.V. Liquid anti-rabies antibody formulations

Also Published As

Publication number Publication date
CN101557799A (zh) 2009-10-14
US7959922B2 (en) 2011-06-14
EP2088997A1 (en) 2009-08-19
JP5410985B2 (ja) 2014-02-05
KR101522036B1 (ko) 2015-05-20
EP2088997B1 (en) 2016-08-24
AU2007328960B2 (en) 2013-01-17
EA200970533A1 (ru) 2009-10-30
CA2668947C (en) 2017-02-07
CN101557799B (zh) 2012-08-22
IL199004A (en) 2015-10-29
IL199004A0 (en) 2010-02-17
ZA200902772B (en) 2012-09-26
EA017549B1 (ru) 2013-01-30
JP2010511665A (ja) 2010-04-15
AU2007328960A1 (en) 2008-06-12
KR20090089881A (ko) 2009-08-24
WO2008068246A1 (en) 2008-06-12
CU23795A3 (es) 2012-03-15
US20100034829A1 (en) 2010-02-11
CA2668947A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
TW200745161A (en) Stable antibody formulation
CR10555A (es) Vacunas para malaria
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
CL2008002885A1 (es) Anticuerpo anti-receptor de interleucina-6 (il-6); y composicion farmaceutica que lo comprende
EA201100268A1 (ru) Вакцина
EA200702616A1 (ru) Дозированная форма для перорального применения
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
DK2044076T3 (da) Fremgangsmåde til fremstilling af asenapin og intermediatprodukter, som anvendes i fremgangsmåden
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
DK2118006T3 (da) Fremgangsmåde til fremstilling af silicapræparater, silicapræparater samt anvendelser deraf
EA201200484A1 (ru) Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
EP2539354A4 (en) FOR RANTES-CODING NUCLEIC ACID MOLECULES AND COMPOSITIONS AND METHODS THEREWITH
EA201171414A1 (ru) Ингибиторы белков семейства iap

Legal Events

Date Code Title Description
FG Grant or registration